GeneDx provided 2025 revenue guidance of $350 million to $360 million, projecting at least 30% growth in exome and genome volume and revenue. Feeley indicated that the company expects to maintain ...

GeneDx’s industry leading exome and genome empower clinicians with comprehensive genetic insights to uncover genetic factors contributing to CP. The testing provides valuable information that ...

Management expects GeneDx (WGS) to deliver full year 2025: Revenues between $350 and $360 million and growth in exome/genome volume and revenue of at least 30%; Adjusted gross margins between 65% ...

The fourth quarter capped an outstanding year for GeneDx (WGS), as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and genome testing for an ever ...

"The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and genome testing for an ever ...

GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash. Click here for more on WGS stock ...

Multiscore, a Gene Ranker Powered by Artificial Intelligence and Real-World Clinical Data, Shows High Sensitivity in 10,000 Exomes and Genomes will be presented by Vinnie Ustach, PhD (GeneDx) on ...

This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path to ...

February 18, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... only previously available to family members for trio testing and for all exome testing. Added content: expanded the number ...

Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes with positive findings in exome and genome ...